Here’s what you should know:
1. Despite a 19.7 percent year-over-year increase, the company’s revenues were lower than Zacks’ estimated $68.5 million.
2. Ironwood reported adjusted losses of $0.28 per share. The losses were higher than Zacks’ estimated $0.23 per share.
3. Ironwood’s key product Linzess generated $167.8 million in sales. As per an agreement, Ironwood splits Linzess sales with Allergan. Ironwood’s net profits from Linzess amounted to $43.8 million.
4. Linzess prescriptions increased 15 percent in the second quarter, surpassing 750,000.
More articles on gastroenterology:
Nevada Supreme Court overturns 2nd-degree murder conviction against gastroenterologist linked to Las Vegas hepatitis C outbreak — 4 insights
Olympus to pay $6.6M in duodenoscope-related damages — 6 key takeaways
Renewed interest in gastroparesis research brings cure into focus — 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
